Products with Anticancer bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN3349 | 7,3'-Dihydroxy-5'-methoxyisoflavone |
| 1. 7,3'-Dihydroxy-5'-methoxyisoflavone shows moderate activity against the renal, melanoma and breast cancer cell lines. 2. 7,3'-Dihydroxy-5'-methoxyisoflavone may have a synergistic effect with other anticancer drugs. | |
| BCN3354 | beta-Amyrenonol methylthiomethyl ether |
| BCN3364 | Alisol B |
| 1. Alisol B can suppress C3a induced epithelial-mesenchymal transition . 2. Alisol B may be a potential novel therapeutic molecule for bone disorders through targeting the differentiation of osteoclasts as well as their functions. 3. Alisol B also inhibited RANKL-induced expression of NFATc1 and c-Fos, which are key transcription factors for osteoclastogenesis. 4. The molecular target of Alisol B is the sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase, it provides detailed insights into the cytotoxic mechanism of a novel antitumor compound. | |
| BCN3374 | Cyclomulberrin |
| 1. Cyclomulberrin exhibits potent inhibition of human PLC/PRF/5 and KB cells in-vitro. 2. Cyclomulberrin shows strong inhibition of arachidonic acid (AA)- and collagen-induced platelet aggregation. 3. Cyclomulberrin also shows slight but significant antiplatelet effects on the aggregation induced by PAF. 4. Cyclomulberrin enhances cell viability in a dose-dependent manner against sodium nitroprusside-induced cell death in neuroblastoma SH-SY5Y cells. | |
| BCN3387 | Lasiodin |
| 1. lasiokaurin has anti-oxidative action. 2. lasiokaurin shows antibacterial activity, esp. against Sarcina lutea. 3. lasiokaurin shows antineoplastic activity against Ehrlich ascites carcinoma. | |
